Join now to get access to this content and more.
Become a SOAP member and have access to our benefits.
- For Review: SOAP Consensus Statement on Neuraxial Procedures in Thrombocytopenic Parturients
- Sample Centers of Excellence Applications
- ASA Corner
- SOAP Policy and Procedure Manual (P&P Manual)
- SOAP Expert Opinions
- SOAP's Learning Modules
- 2019 Annual Meeting Lecture Videos
- December 2018 - SOAP Unofficial Guide to ASA Committees Webinar
- Submit a Position
- View Job Postings
- Previous Meeting Archives
- Previous Meeting Abstract Search
- CMS Guidelines
- Member Benefits
- Newsletter Clinical Articles
- ACOG Documents
- Search our Patient Safety Archive
- Ask SOAP a Question
- Global Health Opportunities
- And more…
COMPARISON OF ANTIMICROBIAL EFFECTS OF DIFFERENT CONCENTRATIONS OF LONG-ACTING LOCAL ANESTHETICS AT DIFFERENT TEMPERATURES
Abstract Number: F3B-4
Abstract Type: Original Research
Aim: Short, medium and long acting local anesthetics demonstrated antibacterial activity against various bacteria strains. Bupivacaine (0.25%), lidocaine 1.25%) and chloroprocaine (0.75%) particularly inhibited growth of S.aureus, whereas articaine, bupivacaine and ropivacaine being relatively weak had antibacterial effect on skin flora bacteria like E.coli, S.aureus and P.aeruginosa (1-3). We aimed to investigate the antimicrobial (antibacterial or antifungal) activity of ropivacaine, levobupivacaine and bupivacaine on S. aureus ATCC 6538, S. epidermidis, E.coli and c.albicans at room and body temperatures.
Methods: Antimicrobial effects of ropivacaine, levobupivacaine and bupivacaine at 24°C (as room temperature) and 37°C (as body temperature) on S. aureus ATCC 6538, S. epidermidis, E. coli and C.albicans ATCC 10231, isolated from blood samples in the microbiology laboratory were investigated. Commercially available local anesthetics were diluted with saline to prepare study and control groups:
-Ropivacaine (Naropin®Ampule 1% 20 ml injektions-lösung,AstraZeneca)
1%, 0.75%, 0.5%, 0.25% and 0.125% (5 concentrations X 4 microorganisms=20)
-Levobupivacaine (Chirocaine®Ampule, 0.75% 10 ml,Abbott) 0.75%, 0.5%,
0.25% and 0.125% (4 concentrations X 4 microorganisms=16)
-Bupivacaine (Marcaine®0.5% injection solution flacon 20 ml, AstraZeneca) 0.5%, 0.25% and 0.125% (3 concentrations X 4 microorganisms=12)
Group 24°C (n= 48) & Group 37°C (n= 48)
Control Group 24°C (n= 4) & Control Group 37°C (n= 4)
Experiment protocol: 0.5 McFarland of bacteria strain and germ suspension was added to tubes
containing local anesthetic and 1 ml of nutrient broth. After collection of samples from groups 24°C and 37°C, they were kept 3, 12 and 24 hours (h) and incubated in nutrient agar. They were kept in the etuv for 24 hours. Microbial growth in plaques were indicated as (+) or ( -).
Results: Three local anesthetics showed antifungal activity until 12 h at room and body temperatures. Levobupivacaine 0.75% showed antibacterial effect until 12 h, whereas levobupivacaine 0.5% had antibacterial activity except E. coli at 37 °C until 12 h Ropivacaine 1% was with more antibacterial activity until 3 and 12 h at 37 °C rather than 24 °C whereas bupivacaine had less.
Discussion: This is the 1st study showing ropivacaine's and levobupivacaines's antifungal activity. Ropivacaine 1% and levobupivacaine 0.75% showed antibacterial activity against all bacterial strains until 12 h. In conclusion, antifungal activity of 3 local anesthetics in addition to antibacterial effect of ropivacaine and levobupivacaine might be beneficial in regional anesthesia practice.
1. Period Biol 2013
2. Int J Obstet Anesth 2002
3. Turk J Med Sci 2007